Difference between revisions of "Part:BBa K209442"
Line 9: | Line 9: | ||
Reference: | Reference: | ||
Delineation of muscarinic receptor domains conferring selectivity of coupling to guanine nucleotide-binding proteins and second messengers. Wess J, Bonner TI, Dörje F, Brann MR. Mol Pharmacol. 1990 Oct;38(4):517-23. | Delineation of muscarinic receptor domains conferring selectivity of coupling to guanine nucleotide-binding proteins and second messengers. Wess J, Bonner TI, Dörje F, Brann MR. Mol Pharmacol. 1990 Oct;38(4):517-23. | ||
+ | |||
+ | ===Documentation and characterization=== | ||
+ | Behavior of cells expressing the chimeric receptor is documented here: http://2009.igem.org/Team:UCSF/Navigation | ||
+ | |||
+ | |||
+ | |||
<!-- --> | <!-- --> |
Latest revision as of 21:20, 1 November 2009
AarI B-C part, M3/M2 chimera
M3/M2 chimera DREADD flanked by AarI BC sites.
Usage and Biology
This M3/M2 chimeric receptor consists of the human M3 muscarinic receptor with the i3 loop from M2 muscarinic receptor. This is an engineered version of the GPCR that can be activated by the otherwise inert small molecule, clozapine-N-oxide.
Reference: Delineation of muscarinic receptor domains conferring selectivity of coupling to guanine nucleotide-binding proteins and second messengers. Wess J, Bonner TI, Dörje F, Brann MR. Mol Pharmacol. 1990 Oct;38(4):517-23.
Documentation and characterization
Behavior of cells expressing the chimeric receptor is documented here: http://2009.igem.org/Team:UCSF/Navigation
Sequence and Features
Assembly Compatibility:
- 10COMPATIBLE WITH RFC[10]
- 12INCOMPATIBLE WITH RFC[12]Illegal NheI site found at 1314
- 21INCOMPATIBLE WITH RFC[21]Illegal BamHI site found at 936
Illegal XhoI site found at 128 - 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]